Show simple item record

dc.creatorParanos, Svetlana
dc.creatorPetrović, Spomenka
dc.date.accessioned2021-02-18T10:19:47Z
dc.date.available2021-02-18T10:19:47Z
dc.date.issued1997
dc.identifier.issn1018-9068
dc.identifier.urihttp://intor.torlakinstitut.com/handle/123456789/73
dc.description.abstractIn this study we assessed the effects of Dermatophagoides pteronyssinus (Dpt) rush immunotherapy in comparison with placebo treatment in our asthmatic patients. Fourteen highly Dpt-susceptible adults were randomized in two groups (immunotherapy and placebo) and treated in single-blind manner. Patients were selected according to the recommendation of the immunotherapy position paper (1993). To minimize side effects we modified the protocol by adjusting allergen doses for each patient separately. Immunologic (total and Dpt-specific serum IgE and IgG antibodies/EIA, Pharmacia) and clinical parameters (spirometry, medication score and skin testing) were recorded before treatment, after 2 weeks, at the second month and after 4 months of immunotherapy onset. None of the patients had life-threatening side effects in the course of the treatment. The results obtained demonstrated significant influence of immunotherapy on Dpt-specific serum IgG synthesis (Kruskal Wallis test, p < 0.05) and on the late phase skin reaction with Dpt (U-test, p < 0.05) at the end of the second month of immunotherapy onset. In the immunotherapy group, we also registered a negative correlation between concentrations of Dpt-specific serum IgE and IgG antibodies (p = -0.83; p < 0.05), at the end of the second month. In addition, diversities among patients, expressed by immunologic parameters, were related to the amount of delivered allergen. There were no significant differences between groups concerning medication score from opposite to better FEV1, PEFR and dPEFR results (Kruskal Wallis, p < 0.05) in the placebo group. In conclusion, Dpt-specific serum IgG concentration, immunologic score and late phase skin reactivity to allergen appeared to be the valid parameters of rush-immunotherapy achievement, while delivered allergen dose also seemed to be an influencing factor.en
dc.rightsrestrictedAccess
dc.sourceJournal of Investigational Allergology and Clinical Immunology
dc.subjectAsthmaen
dc.subjectDermatophagoidesen
dc.subjectImmunotherapyen
dc.subjectPteronyssinusen
dc.subjectRushen
dc.titleEarly effects of rush immunotherapy with Dermatophagoides pteronyssinus in asthmaticsen
dc.typearticle
dc.rights.licenseARR
dc.citation.epage595
dc.citation.issue6
dc.citation.other7(6): 588-595
dc.citation.spage588
dc.citation.volume7
dc.identifier.pmid9491200
dc.identifier.rcubconv_539
dc.identifier.scopus2-s2.0-0031454765
dc.type.versionpublishedVersion


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record